Please sign in to follow a disease.
Hemophagocytic syndrome
MONDO:0015540Hemophagocytic syndrome (HPS) is a rare immune disease and a potentially life-threatening disorder characterized by cytokine storm and overwhelming inflammation causing fever, hepatosplenomegaly, cytopenia, hypertriglyceridemia, hyperferritinemia, and hemophagocytosis in bone marrow, liver, spleen or lymph nodes. It can be either primary due to a genetic defect (primary hemophagocytic lymphohistiocytosis), or secondary to malignancies, to infections, most commonly with viruses such as Epstein-Barr virus or cytomegalovirus, human immunodeficiency virus, or to autoimmune disorders such as systemic lupus erythematosus or adult-onset Still disease (secondary hemophagocytic lymphohistiocytosis).
Also known as: HLH, Hemophagocytic Lymphohistiocytosis, hemophagocytic lymphohistiocytosis, hemophagocytic syndrome, FHL, familial erythrophagocytic lymphohistiocytosis, familial hemophagocytic lymphohistiocytosis, familial histiocytic reticulosis
58 clinical trials for this condition and its sub-types, 38 tagged with Hemophagocytic syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hemophagocytic syndrome
-
Secondary hemophagocytic lymphohistiocytosis 15 trials · 24 incl. sub-types
2 sub-types
-
Hereditary hemophagocytic lymphohistiocytosis 8 trials · 16 incl. sub-types
11 sub-types
- Chediak-Higashi syndrome 9 trials
- Griscelli syndrome type 2 1 trial
- Familial hemophagocytic lymphohistiocytosis 3 1 trial
- Hermansky-Pudlak syndrome 2 0 trials
- Hermansky-Pudlak syndrome 9 0 trials
- Familial hemophagocytic lymphohistiocytosis 2 0 trials
- Familial hemophagocytic lymphohistiocytosis 4 0 trials
- Familial hemophagocytic lymphohistiocytosis 5 0 trials
- Familial hemophagocytic lymphohistiocytosis type 1 0 trials
- Hemophagocytic lymphohistiocytosis due to RhoG deficiency 0 trials
- Hemophagocytic lymphohistiocytosis, familial, 6 0 trials
-
New hope for adults with HLH: gentler treatment combo under study
Disease control Recruiting nowThis phase 2 trial is testing a combination of ruxolitinib and a reduced-intensity version of the standard HLH-94 regimen (dexamethasone and etoposide) in 36 adults newly diagnosed with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system attacks the…
Phase 2 • Sponsor: Jerry Lee, MD, MSc, MPhil • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Milder chemo may make stem cell transplants safer for Non-Cancer patients
Disease control Recruiting nowThis phase 2 trial tests a combination of three chemotherapy drugs (treosulfan, fludarabine, thiotepa) plus an immune-suppressing antibody before a donor stem cell transplant in up to 40 people under 50 with non-cancerous blood disorders. The goal is to see if this milder conditi…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug could tame deadly immune storm in kids before transplant
Disease control Recruiting nowThis study tests a drug called ruxolitinib as the first treatment for children with a rare, life-threatening immune condition called primary HLH. The goal is to calm the overactive immune system and help more children survive long enough to receive a stem cell transplant. The tri…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New immune cell boost may shield kids from Post-Transplant infections
Disease control Recruiting nowThis study tests whether adding memory immune cells (CD45RO) to a stem cell transplant can help children fight off dangerous viral and fungal infections after the procedure. The transplant uses donor stem cells that have been stripped of certain cells to prevent graft-versus-host…
Phase 1/2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for deadly lymphoma combo: drug cocktail targets both cancer and immune chaos
Disease control Recruiting nowThis trial tests a new combination of drugs (MEPL-G) for people with a rare and aggressive lymphoma (NK/T-cell) that has triggered a life-threatening immune overreaction called HLH. The goal is to control both the cancer and the dangerous inflammation quickly. About 25 adults wil…
Phase 1/2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Cord blood transplants offer hope for kids without a donor match
Disease control Recruiting nowThis study tests a cord blood transplant in children and young adults (up to age 21) with life-threatening blood cancers or non-cancer blood disorders who do not have a matched family donor. The goal is to see if this approach lowers the risk of death from treatment one year afte…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug aims to tame dangerous immune reactions from cancer therapy
Disease control Recruiting nowThis early-phase study tests whether an investigational drug called Tadekinig alfa can safely and feasibly treat severe immune overreactions (CRS and HLH-like syndrome) that can occur after CAR T cell therapy. Ten adult participants who are already in a CAR T cell trial will rece…
Early phase 1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug duo takes on stubborn Epstein-Barr virus
Disease control Recruiting nowThis study tests whether combining two drugs, golidocitinib and selinexor, can control chronic active Epstein-Barr virus disease (CAEBVD). Researchers will enroll 28 adults with CAEBVD and track how well the treatment reduces symptoms and lowers virus levels in the blood. It is a…
Phase 2/3 • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for HLH patients: targeted drug tested in clinical trial
Disease control Recruiting nowThis study tests a drug called golidocitinib for people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system attacks the body. The trial will include 28 people aged 14 to 70 with newly diagnosed or returning HLH. The goal is to see if the drug c…
Phase 2/3 • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug cocktail aims to tame deadly immune storm in lymphoma
Disease control Recruiting nowThis study tests a combination of two drugs, zanubrutinib and rituximab, for people with B-cell lymphoma who develop a severe immune overreaction called hemophagocytic lymphohistiocytosis (HLH). The trial will enroll 40 participants and aims to see how well the treatment controls…
Phase 4 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Researchers launch study to unravel mysteries of rare immune disorder sHLH
Knowledge-focused Recruiting nowThis study aims to understand why some adults develop secondary hemophagocytic lymphohistiocytosis (sHLH), a serious immune condition causing fevers and organ damage. Researchers will follow 300 participants for up to 3 years, collecting blood samples and medical data to identify…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Can a national registry crack the code of a rare childhood disease?
Knowledge-focused Recruiting nowThis study aims to create a national registry in Egypt for children diagnosed with hemophagocytic lymphohistiocytosis (HLH), a rare and serious immune disorder. Researchers will collect data from hospitals across the country to build a detailed map of how the disease presents in …
Sponsor: Ain Shams University • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Massive study tracks hidden toll of rare immune diseases
Knowledge-focused Recruiting nowThis study follows 6,000 people with histiocytic disorders (like Langerhans cell histiocytosis) to understand long-term health problems, pain, mental health, and causes of death. Researchers compare participants to healthy controls to identify factors that lead to new health issu…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New study sheds light on mysterious immune disease in adults
Knowledge-focused Recruiting nowThis study is following 81 adults with a rare condition called hemophagocytic lymphohistiocytosis (HLH), where the immune system becomes dangerously overactive. Researchers aim to better understand the disease's features and how patients respond to treatments like steroids and ch…
Sponsor: Samsung Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New HLH registry aims to unlock secrets of rare immune disease
Knowledge-focused Recruiting nowThis study is a registry that collects information from 200 people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system becomes dangerously overactive. Researchers will track how quickly HLH is diagnosed, what treatments are used, and what compl…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Large study aims to uncover best treatments for lymphoma patients with dangerous immune reaction
Knowledge-focused Recruiting nowThis study is observing 2,000 lymphoma patients who also develop hemophagocytic lymphohistiocytosis (HLH), a severe immune overreaction. Researchers will collect data on which treatments patients receive and how they respond, aiming to identify factors that improve survival at 18…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
ICU liver patients: new study tests HLH diagnostic tool
Knowledge-focused Recruiting nowThis study looks at whether a tool called the HScore can accurately diagnose hemophagocytic lymphohistiocytosis (HLH) in intensive care patients with liver failure or cirrhosis. Researchers will review medical records of 100 adults admitted to one hospital over ten years who had …
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Massive registry launched to see if Blood-Filtering device helps sickest patients
Knowledge-focused Recruiting nowThis registry is tracking 3,000 critically ill patients who receive the CytoSorb blood-filtering device in real-world intensive care settings. The goal is to collect data on how the device is used and whether it relates to patient survival. It covers many conditions like sepsis, …
Sponsor: CytoSorbents, Inc • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:43 UTC